Effects of Grape Powder on Psychological Distress and Gut Microbiota in College Students
1 other identifier
interventional
50
1 country
1
Brief Summary
The goal of this trial is to investigate the effect of freeze-dried table grape powder (FTGP) on psychological distress and gut microbiota in college students. The main questions it aims to answer are: Does FTGP reduce anxiety, depression, and perceived stress? Does FTGP improve the gut microbiota? Researchers will compare FTGP to a placebo to see how FTGP affects psychological distress and gut microbiota. Participants will: Drink a daily supplement containing FTGP or a placebo for 4 weeks. Record consumption of grape powder or placebo in a compliance log. Complete surveys and provide stool samples. Three in-person visits.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P25-P50 for not_applicable
Started Oct 2025
Shorter than P25 for not_applicable
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
October 1, 2025
CompletedFirst Posted
Study publicly available on registry
October 9, 2025
CompletedStudy Start
First participant enrolled
October 20, 2025
CompletedPrimary Completion
Last participant's last visit for primary outcome
December 24, 2025
CompletedStudy Completion
Last participant's last visit for all outcomes
May 30, 2026
ExpectedJanuary 15, 2026
January 1, 2026
2 months
October 1, 2025
January 14, 2026
Conditions
Keywords
Outcome Measures
Primary Outcomes (3)
Hamilton Anxiety Scale -14
HAMA-14 is one of the earliest and most widely used clinical scales for measuring the severity of a patient's anxiety. It has 14 items, each reflecting a cluster of anxiety symptoms. Total range: 0 to 56, with higher scores indicating greater severity of anxiety
baseline (1st), week 4 (2nd) and week 5 (3rd)
17-item of Hamilton Depression Rating Scale
HAMD-17 is one of the most widely used clinician-administered scales for measuring the severity of a patient's depression. It has 17 items, each covering symptoms of depression across mood, physical, and cognitive domains. With higher scores indicating greater severity of depression.
baseline (1st), week 4 (2nd) and week5 (3rd)
10-item of Perceived Stress Scale
PSS-10 is one of the most widely used psychological instruments for measuring the perception of stress. It has 10 items, each reflecting how unpredictable, uncontrollable, and overloaded respondents find their lives during the past month. Total range: 0 to 40, with higher scores indicating greater perceived stress.
baseline (1st), week 4 (2nd) and week5 (3rd)
Secondary Outcomes (3)
Shannon Index of gut microbiota
baseline (1st), week 4 (2nd) and week5 (3rd)
Beta diversity of gut microbiota
baseline (1st), week 4 (2nd) and week 5 (3rd)
fecal short chain fatty acid
baseline (1st), week 4 (2nd) and week5 (3rd)
Study Arms (2)
freeze-dried table grape powder (FTGP)
EXPERIMENTALDrink a daily supplement containing FTGP for 4 weeks
Placebo
PLACEBO COMPARATORDrink a daily supplement containing a placebo for 4 weeks
Interventions
48g freeze-dried table grape powder/day for 4 weeks
Eligibility Criteria
You may qualify if:
- Aged 18-30 years old
- Able to give written informed consent.
- BMI 18.5-24.9 kg/m2
- Healthy (self-reported)
- Can read and speak English
You may not qualify if:
- Currently taking medications that interfere with polyphenol
- Currently using or have used antibiotics continuously for \>3 days within 3 months prior to enrollment
- Have had surgery involving the intestinal lumen within the last 30 days
- Have a documented diagnosis of celiac disease or/and inflammatory bowel diseases
- Are pregnant or breastfeeding
- Have prediabetes and diabetes
- Have had bariatric surgery
- Are immunocompromised ( e.g., cancer treatment, bone marrow/organ transplant, immune deficiency, or poorly controlled HIV/AIDS)
- Are unable to provide consent
- Are hospitalized,
- Have a history of or current alcohol, drug, or medication abuse (self-reported),
- Have contraindication to any substance in the investigational product or who are currently enrolled in other interventional trials
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Department of Biochemistry and Microbiology, School of Environmental and Biological Sciences, Rutgers, The State University of New Jersey
New Brunswick, New Jersey, 08901, United States
Study Officials
- PRINCIPAL INVESTIGATOR
Guojun Wu
Rutgers, The State University of New Jersey
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- DOUBLE
- Who Masked
- PARTICIPANT, INVESTIGATOR
- Purpose
- BASIC SCIENCE
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Assistant Research Professor
Study Record Dates
First Submitted
October 1, 2025
First Posted
October 9, 2025
Study Start
October 20, 2025
Primary Completion
December 24, 2025
Study Completion (Estimated)
May 30, 2026
Last Updated
January 15, 2026
Record last verified: 2026-01
Data Sharing
- IPD Sharing
- Will not share
IPD might not be shared according to the consent form.